IP Library › Granted Patent US 12,733,842
Granted Patent B2
US 12,733,842 · App. 15/060,401 · Granted Sep 15, 2026

System and method for mode switching

Inventors: Naresh C. Bhavaraju (San Diego, CA); Michael A. Bloom (Carlsbad, CA); Leif N. Bowman (San Diego, CA); Alexandra Lynn Carlton (San Marcos, CA); Katherine Yerre Koehler (Solana Beach, CA); Hari Hampapuram (Carlsbad, CA); Jonathan Hughes (Encinitas, CA); Lauren Hruby Jepson (San Diego, CA); Apurv Ulas Kamath (San Diego, CA); Anna Leigh Davis (Cardiff by the Sea, CA); Peter C. Simpson (Cardiff, CA); Stephen J. Vanslyke (Carlsbad, CA)
Assignee: Dexcom, Inc.
A61B5/14532A61B5/0002A61B5/14503A61B5/14546A61B5/1455A61B5/1486A61B5/1495A61B5/7221A61B5/7275A61B5/7282A61B5/742A61B5/7435A61B5/746A61B5/7475A61M5/1723G16H40/40G16H40/63A61B5/0004A61B5/6898A61B5/72A61B2560/0223A61B2560/0487A61M2230/005A61M2230/201Y02A90/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,733,842
App. No.
15/060,401
Granted
Sep 15, 2026
Kind
B2
Abstract

Systems and methods described provide dynamic and intelligent ways to change the required level of user interaction during use of a monitoring device. The systems and methods generally relate to real time switching between a first or initial mode of user interaction and a second or new mode of user interaction. In some cases, the switching will be automatic and transparent to the user, and in other cases user notification may occur. The mode switching generally affects the user's interaction with the device, and not just internal processing. The mode switching may relate to calibration modes, data transmission modes, control modes, or the like.

Claims (25)

1 . A method of automatically changing modes in a diabetes management system, comprising:

operating a monitoring device in a therapeutic mode during which glucose of a user is monitored and the monitored glucose is used to base insulin dosing decisions for the user;

while operating the monitoring device in the therapeutic mode, operating the monitoring device in a first calibration mode;

performing a first transition to operate the monitoring device in a non-therapeutic mode during which glucose of the user is monitored and glucose information is provided to the user, but the monitored glucose is not used to base insulin dosing decisions for the user, wherein criteria for performing the first transition are at least partially based on a glucose range of a current glucose value of the user and a time-of-day; and

responsive to the first transition, performing a second transition to operate the monitoring device in a second calibration mode, wherein the first calibration mode comprises one of a user-dependent calibration mode or a factory calibration mode and wherein the second calibration mode comprises a different one of the user-dependent calibration mode or the factory calibration mode.

2 . The method of claim 1 , wherein the first calibration mode is the user-dependent calibration mode, and wherein the second calibration mode is the factory calibration mode.

3 . The method of claim 1 , wherein the first calibration mode is the factory calibration mode, and wherein the second calibration mode is the user-dependent calibration mode, and wherein second criteria for performing the second transition include a number of blood glucose measurements entered into the monitoring device as calibration values exceeding a predetermined threshold over a predetermined period of time.

4 . The method of claim 1 , wherein the first transition is further based on a level of data usability passing a threshold.

5 . The method of claim 1 , wherein the therapeutic mode is a first phase of an artificial pancreas system, and wherein the non-therapeutic mode is a second phase of the artificial pancreas system.

6 . The method of claim 1 , further comprising displaying an indication of the therapeutic mode or the non-therapeutic mode on a user interface, and wherein providing the glucose information to the user comprises causing display of the glucose information on the user interface.

7 . The method of claim 1 , wherein the first transition is caused by data received from sensor electronics, data from diagnostic routines, or signal quality data.

8 . A method of automatically changing modes in a diabetes management system, comprising:

operating a monitoring device in a non-therapeutic mode during which glucose of a user is monitored and glucose information is provided to the user, but the monitored glucose is not used to base insulin dosing decisions for the user;

while operating the monitoring device in the non-therapeutic mode, operating the monitoring device in a first calibration mode;

performing a first transition to operate the monitoring device in a therapeutic mode during which glucose of the user is monitored and the monitored glucose is used to base insulin dosing decisions for the user, wherein criteria for performing the first transition are at least partially based on a glucose range of a current glucose value of the user and a time-of-day; and

responsive to the first transition, performing a second transition to operate the monitoring device in a second calibration mode, wherein the first calibration mode comprises one of a user-dependent calibration mode or a factory calibration mode and wherein the second calibration mode comprises a different one of the user-dependent calibration mode or the factory calibration mode.

9 . The method of claim 8 , wherein the first transition is further based on a level of data usability passing a threshold.

10 . The method of claim 8 , further comprising displaying at least one of an indication of the non-therapeutic mode or the therapeutic mode on a user interface.

11 . The method of claim 1 , wherein the first calibration mode is the user-dependent calibration mode, and wherein the second calibration mode is the factory calibration mode.

12 . The method of claim 1 , wherein, during the therapeutic mode, insulin is delivered to the user, and wherein, during the non-therapeutic mode, insulin is not delivered to the user.

13 . The method of claim 1 , wherein, during the therapeutic mode, recommendations are provided to the user, and wherein, during the non-therapeutic mode, the recommendations are not provided to the user.

14 . The method of claim 1 , wherein the glucose range of the current glucose value of the user is hyperglycemia, and the time-of-day is daytime.

15 . The method of claim 1 , wherein second criteria for performing the second transition are based on a patient specific glucose profile or a level of confidence in a sensor of the monitoring device reaching a predetermined threshold.

16 . The method of claim 1 , wherein the user-dependent calibration mode comprises a calibration routine that uses blood glucose concentration values from an external meter, and the factory calibration mode comprises a different calibration routine performed by the monitoring device without the blood glucose concentration values from the external meter.

17 . The method of claim 8 , wherein the glucose range of the current glucose value of the user is hypoglycemia, and the time-of-day is nighttime.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2016
From: GRUBSTEIN, KATHERINE YERRE
To: DEXCOM, INC.
Reel/Frame 037921/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2016
From: BOWMAN, LEIF N.; BHAVARAJU, NARESH C.; BLOOM, MICHAEL A.; CARLTON, ALEXANDRA LYNN; HAMPAPURAM, HARI; JEPSON, LAUREN HRUBY; HUGHES, JONATHAN; KAMATH, APURV ULLAS; RACK-GOMER, ANNA LEIGH; SIMPSON, PETER C.; VANSLYKE, STEPHEN J.
To: DEXCOM, INC.
Reel/Frame 037896/0548 →
Continuity (3)
Continuation 14862079 · Sep 22, 2015
Provisional Application 62053733 · Sep 22, 2014
Related Publication 20160198988A1 · Jul 14, 2016
References Cited (86)
US 5267152A · Yang et al. · 1993 [cited by applicant]
US 7591801B2 · Brauker et al. · 2009 [cited by applicant]
US 7783442B2 · Mueller et al. · 2010 [cited by applicant]
US 7885697B2 · Brister et al. · 2011 [cited by applicant]
US 7946985B2 · Mastrototaro et al. · 2011 [cited by applicant]
US 7976492B2 · Brauker et al. · 2011 [cited by applicant]
US 8423381B2 · Gegner et al. · 2013 [cited by applicant]
US 8442610B2 · Goode et al. · 2013 [cited by applicant]
US 8460231B2 · Brauker et al. · 2013 [cited by applicant]
US 8579879B2 · Palerm et al. · 2013 [cited by applicant]
US 8721585B2 · Brauker et al. · 2014 [cited by applicant]
US 8808228B2 · Brister et al. · 2014 [cited by applicant]
US 8882741B2 · Brauker et al. · 2014 [cited by applicant]
US 8920401B2 · Brauker et al. · 2014 [cited by applicant]
US 8926585B2 · Brauker et al. · 2015 [cited by applicant]
US 9050413B2 · Brauker et al. · 2015 [cited by applicant]
US 9155843B2 · Brauker et al. · 2015 [cited by applicant]
US 9452258B2 · Dobbles et al. · 2016 [cited by applicant]
US 9452259B2 · Dobbles et al. · 2016 [cited by applicant]
US 9457146B2 · Dobbles et al. · 2016 [cited by applicant]
US 9463277B2 · Dobbles et al. · 2016 [cited by applicant]
US 20030100846A1 · Custer et al. · 2003 [cited by applicant]
US 20050027180A1 · Goode, Jr. · 2005 [cited by examiner]
US 20050043598A1 · Goode, Jr. et al. · 2005 [cited by applicant]
US 20060020192A1 · Brister et al. · 2006 [cited by applicant]
US 20070208246A1 · Brauker et al. · 2007 [cited by applicant]
US 20070258395A1 · Jollota · 2007 [cited by examiner]
US 20080161664A1 · Mastrototaro et al. · 2008 [cited by applicant]
US 20080228045A1 · Gao et al. · 2008 [cited by applicant]
US 20080234663A1 · Yodfat et al. · 2008 [cited by applicant]
US 20090005666A1 · Shin et al. · 2009 [cited by applicant]
US 20090006034A1 · Hayter et al. · 2009 [cited by applicant]
US 20090112478A1 · Mueller, Jr. · 2009 [cited by examiner]
US 20090178459A1 · Li et al. · 2009 [cited by applicant]
US 20090192366A1 · Mensinger et al. · 2009 [cited by applicant]
US 20100057041A1 · Hayter · 2010 [cited by applicant]
US 20100138197A1 · Sher · 2010 [cited by examiner]
US 20100174168A1 · Goode, Jr. et al. · 2010 [cited by applicant]
US 20100249561A1 · Patek et al. · 2010 [cited by applicant]
US 20100262434A1 · Shaya · 2010 [cited by applicant]
US 20100332142A1 · Shadforth et al. · 2010 [cited by applicant]
US 20110015944A1 · Gegner et al. · 2011 [cited by applicant]
US 20110178820A1 · Soni et al. · 2011 [cited by applicant]
US 20110191044A1 · Stafford · 2011 [cited by applicant]
US 20110213559A1 · Pollack et al. · 2011 [cited by applicant]
US 20120029942A1 · Katsuki · 2012 [cited by examiner]
US 20120078071A1 · Bohm et al. · 2012 [cited by applicant]
US 20120083714A1 · Yuen et al. · 2012 [cited by applicant]
US 20120108935A1 · Liang et al. · 2012 [cited by applicant]
US 20120125075A1 · Gottlieb et al. · 2012 [cited by applicant]
US 20120220979A1 · Brauker et al. · 2012 [cited by applicant]
US 20120265037A1 · Böhm et al. · 2012 [cited by applicant]
US 20120271557A1 · Seikmoto et al. · 2012 [cited by applicant]
US 20130218126A1 · Hayter et al. · 2013 [cited by applicant]
US 20140000338A1 · Luo et al. · 2014 [cited by applicant]
US 20140005505A1 · Peyser et al. · 2014 [cited by applicant]
US 20140012510A1 · Mensinger et al. · 2014 [cited by applicant]
US 20140039383A1 · Dobbles et al. · 2014 [cited by applicant]
US 20140277286A1 · Cinbis · 2014 [cited by applicant]
US 20140288494A1 · Brister et al. · 2014 [cited by applicant]
US 20150164387A1 · Varsavsky · 2015 [cited by examiner]
US 20150165117A1 · Palerm et al. · 2015 [cited by applicant]
US 20160081597A1 · Bhavaraju et al. · 2016 [cited by applicant]
US 20160106350A1 · Bhavaraju et al. · 2016 [cited by applicant]
US 20160113557A1 · Bhavaraju et al. · 2016 [cited by applicant]
US 20160113558A1 · Bhavaraju et al. · 2016 [cited by applicant]
US 20190328291A1 · Bhavaraju et al. · 2019 [cited by applicant]
US 20190328292A1 · Bhavaraju et al. · 2019 [cited by applicant]
EP 1718350B1 · 2013 [cited by applicant]
GB 2488487A · 2012 [cited by applicant]
WO 2004109992A1 · 2004 [cited by applicant]
WO WO2008086541A9 · 2008 [cited by applicant]
WO WO2008086541A3 · 2008 [cited by applicant]
WO 2012178134A2 · 2012 [cited by applicant]
WO WO2015156965 · 2015 [cited by applicant]
WO 2015187366A1 · 2015 [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2015/051548 mailed on Apr. 6, 2017, 7 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2015/051548 mailed on Dec. 16, 2015, 9 pages. [cited by applicant]
Office Action from Australian Patent Application No. 2019202148, dated Mar. 16, 2021, 3 pages. [cited by applicant]
Office Action from Canadian Patent Application No. 2,953,577, dated May 3, 2021, 5 pages. [cited by applicant]
Office Action from Australian Patent Application No. 2019202148, dated Jan. 20, 2021, 5 pages. [cited by applicant]
Notice of Opposition from European application No. 15778109.7, mailed Sep. 21, 2021, 48 pages. [cited by applicant]
U.S. Appl. No. 62/053,733, inventors Bowman; Leif N. et al., filed Sep. 22, 2014. [cited by applicant]
Bothe M.K., et al., “The use of Reinforcement Learning Algorithms to meet the challenges of an Artificial Pancreas”, Expert Review Medical Devices, vol. 10(5), 2013, pp. 661-673. [cited by applicant]
Dexcom Inc., “Dexcom G4 Platinum Continuous Glucose Monitoring System Quick Start Guide,” 2013, 2 pages. [cited by applicant]
Vaddiraju S., et al., “Technologies for Continuous Glucose Monitoring: Current Problems and Future Promises”, Journal of Diabetes Science and Technology, vol. 4(6), Nov. 2010, pp. 1540-1562. [cited by applicant]